Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
AZTA Stock Overview
Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide.
Azenta Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$70.73 |
52 Week High | US$124.79 |
52 Week Low | US$61.35 |
Beta | 1.66 |
1 Month Change | -9.39% |
3 Month Change | -18.93% |
1 Year Change | -24.52% |
3 Year Change | 97.13% |
5 Year Change | 159.18% |
Change since IPO | 607.30% |
Recent News & Updates
Shareholder Returns
AZTA | US Life Sciences | US Market | |
---|---|---|---|
7D | 1.3% | 4.6% | 2.7% |
1Y | -24.5% | -6.6% | -8.1% |
Return vs Industry: AZTA underperformed the US Life Sciences industry which returned -6.6% over the past year.
Return vs Market: AZTA underperformed the US Market which returned -8.1% over the past year.
Price Volatility
AZTA volatility | |
---|---|
AZTA Average Weekly Movement | 7.4% |
Life Sciences Industry Average Movement | 10.9% |
Market Average Movement | 7.8% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AZTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AZTA's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1978 | 2,900 | Steve Schwartz | https://www.azenta.com |
Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils; instruments, such as labeling, bar coding, capping, de-capping, auditing, sealing, peeling, piercing tubes, and plates.
Azenta Fundamentals Summary
AZTA fundamental statistics | |
---|---|
Market Cap | US$5.64b |
Earnings (TTM) | -US$23.20m |
Revenue (TTM) | US$551.22m |
9.6x
P/S Ratio-227.0x
P/E RatioIs AZTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AZTA income statement (TTM) | |
---|---|
Revenue | US$551.22m |
Cost of Revenue | US$284.78m |
Gross Profit | US$266.44m |
Other Expenses | US$289.64m |
Earnings | -US$23.20m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.31 |
Gross Margin | 48.34% |
Net Profit Margin | -4.21% |
Debt/Equity Ratio | 0% |
How did AZTA perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield-64%
Payout RatioValuation
Is Azenta undervalued compared to its fair value and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
34.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AZTA ($70.73) is trading below our estimate of fair value ($108.03)
Significantly Below Fair Value: AZTA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AZTA is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: AZTA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AZTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AZTA is good value based on its PB Ratio (1.5x) compared to the US Life Sciences industry average (2.2x).
Future Growth
How is Azenta forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-89.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZTA's earnings are forecast to decline over the next 3 years (-89.9% per year).
Earnings vs Market: AZTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AZTA's is expected to become profitable in the next 3 years.
Revenue vs Market: AZTA's revenue (19.9% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: AZTA's revenue (19.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AZTA's Return on Equity is forecast to be low in 3 years time (2.2%).
Past Performance
How has Azenta performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-50.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZTA is currently unprofitable.
Growing Profit Margin: AZTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AZTA is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.
Accelerating Growth: Unable to compare AZTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZTA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).
Return on Equity
High ROE: AZTA has a negative Return on Equity (-0.67%), as it is currently unprofitable.
Financial Health
How is Azenta's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AZTA's short term assets ($3.0B) exceed its short term liabilities ($618.0M).
Long Term Liabilities: AZTA's short term assets ($3.0B) exceed its long term liabilities ($76.1M).
Debt to Equity History and Analysis
Debt Level: AZTA is debt free.
Reducing Debt: AZTA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AZTA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AZTA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Azenta current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.56%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AZTA's dividend (0.57%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.51%).
High Dividend: AZTA's dividend (0.57%) is low compared to the top 25% of dividend payers in the US market (3.97%).
Stability and Growth of Payments
Stable Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: AZTA is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: AZTA is paying a dividend but the company has no free cash flows.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.8yrs
Average management tenure
CEO
Steve Schwartz (62 yo)
11.58yrs
Tenure
US$5,290,656
Compensation
Dr. Stephen S. Schwartz, also known as Steve, is a Director Azenta US, Inc. He is President and Chief Executive Officer at Azenta US, Inc. He has been Chief Executive Officer of Azenta, Inc. (formerly know...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD5.29M) is below average for companies of similar size in the US market ($USD8.19M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: AZTA's management team is seasoned and experienced (7.8 years average tenure).
Board Members
Experienced Board: AZTA's board of directors are seasoned and experienced ( 10.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Azenta, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Azenta, Inc.
- Ticker: AZTA
- Exchange: NasdaqGS
- Founded: 1978
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.644b
- Shares outstanding: 74.43m
- Website: https://www.azenta.com
Number of Employees
Location
- Azenta, Inc.
- 15 Elizabeth Drive
- Chelmsford
- Massachusetts
- 1824
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/18 00:00 |
End of Day Share Price | 2022/05/18 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.